case_images: PMC9928200_01
case_images: (A) Morphology of the patient's lymphoblasts (scale: 10x). (B) Results of our flow cytometry analysis. (C) Karyotype analysis for this patient. (D) Treatment flow chart. (E) Sensitivity of the patient's leukemic cells to 21 drugs tested. Drugs with a relative inhibition rate higher than 50% are listed. (F) MRD values during the treatment period.
case_images: fonc-12-1018250-g001.jpg
case_images: PMC9928200_01_fonc-12-1018250-g001.jpg
case_images: f1
case_images: Figure 1A ). Flow cytometry showed that the blasts were mainly positive for CD45min, CD34, CD10, CD19, CD9, CD56, CD22, CD58, CD81, cCD79a, and HLA-DR, partially positive for CD79b and cTdT, and negative for CD7, CD117, CD33, CD13, CD20, CD15, CD38, cIgM, and MPO, indicating a diagnosis of early-stage B-ALL ( Figure 1B ). Karyotyping analysis of the peripheral blood illustrated that the patient had normal karyotype ( Figure 1C ). Chemotherapy schemes received by the patient are shown in  Figure 1D . Afterwards, the patient received three additional rounds of induction therapy but was still MRD-positive, as detailed in  Figure 1F . Figure 1E . Finally, the patient received the scheme vincristine 1.5 mg/m2 day 1 + cytarabine 2000 mg/m2 days 1-3 + bortezomib 1 mg/m2 days 1 and 5, + fludarabine 25 mg/m2 days 1 -5, and achieved CR and became MRD-negative.